Wed, Oct 1, 2014, 6:47 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Trius Therapeutics, Inc. (TSRX) Message Board

  • lakerfan_dough lakerfan_dough Jun 23, 2012 1:48 PM Flag

    new study

    Quote:
    --------------------------------------------------------------------------------
    This study confirms the potent in vitro activity of tedizolid against pathogenic gram-positive cocci, including MRSA, and 4-fold greater potency compared with linezolid. All dosages of tedizolid phosphate showed excellent microbiological and clinical efficacy against MRSA and MSSA.

    --------------------------------------------------------------------------------


    2012 Jun 11. [Epub ahead of print]
    In Vitro Activity and Microbiological Efficacy of Tedizolid (TR-700) against Gram-Positive Clinical Isolates from a Phase 2 Study of Oral Tedizolid Phosphate (TR-701) in Patients with Complicated Skin and Skin Structure Infections.
    Prokocimer PP, Bien P, Deanda C, Pillar CM, Bartizal K.
    Source
    Trius Therapeutics, Inc., San Diego, California.
    Abstract
    Tedizolid (TR-700, formerly torezolid) is the active moiety of the prodrug tedizolid phosphate (TR-701), a next-generation oxazolidinone, with high potency against gram-positive species, including methicillin-resistant Staphylococcus aureus (MRSA). A recently completed randomized, double-blind phase 2 trial evaluated 200, 300, or 400 mg of oral tedizolid phosphate once daily for 5 to 7 days in patients with complicated skin and skin structure infections. This report examines the in vitro activity of tedizolid and Zyvox® (linezolid) against gram-positive pathogens isolated at baseline and describes the microbiological and clinical efficacy of tedizolid. Of 196 isolates tested, 81.6% were S. aureus, and of these, 76% were MRSA. The MIC(50) and MIC(90) of tedizolid against both methicillin-susceptible S. aureus (MSSA) and MRSA were 0.25 µg/ml, compared with MIC(50) of 1 µg/ml and MIC(90) of 2 µg/ml with linezolid. For coagulase-negative staphylococci (n=7), viridans group streptococci (n=15), and ß-hemolytic streptococci (n=3), MICs ranged from 0.03-0.25 µg/ml for tedizolid and 0.12-1 µg/ml for linezolid. Microbiological eradication rates at the test-of-cure visit (7-14 days post-treatment) in the microbiologically evaluable population (n=133) were similar in all treatment groups, with overall eradication rates of 97.7% for all pathogens, 97.9% for MRSA, and 95.7% for MSSA. Clinical cure rates for MRSA and MSSA infections were 96.9% and 95.7%, respectively, across all dose groups. This study confirms the potent in vitro activity of tedizolid against pathogenic gram-positive cocci, including MRSA, and 4-fold greater potency compared with linezolid. All dosages of tedizolid phosphate showed excellent microbiological and clinical efficacy against MRSA and MSSA.
    PMID: 22687509 [PubMed - as supplied by publisher]

 
TSRX
13.630.00(0.00%)Sep 11 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.